- New agents for Clostridium difficile-associated disease
[作者:Guiles, J; Critchley, I; Sun, X,期刊:Expert opinion on investigational drugs, 页码:1671-1683 , 文章类型: Review,,卷期:2008年17-11]
Background: Clostridia-derived diseases, in particular C. difficile-associated disease (CDAD), have been increasing in incidence, severity, and morbidity. The mainstay of treatment options has relied upon metronidazol...
- Experimental therapy for advanced renal cell carcinoma
[作者:Hutson, TE; Figlin, RA,期刊:Expert opinion on investigational drugs, 页码:1693-1702 , 文章类型: Review,,卷期:2008年17-11]
Background: The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically over the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab +/- interferon-alfa, temsirolimus, and everolimus ...
- Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosareoma)
[作者:Anderson, P; Kopp, L; Anderson, N; Cornelius, K; Herzog, C; Hughes, D; Htth, W,期刊:Expert opinion on investigational drugs, 页码:1703-1715 , 文章类型: Review,,卷期:2008年17-11]
Background: New investigational agents and chemotherapy regimens including cyclophosphamide + topotecan, temozolomide + irinotecan, and anti-IGF-1R antibodies in Ewing's sarcoma (ES) and liposomal muramyl-tripeptide p...
- Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate
[作者:Klar, U; Hoffmann, J; Giurescu, M,期刊:Expert opinion on investigational drugs, 页码:1735-1748 , 文章类型: Review,,卷期:2008年17-11]
Background: Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and docetaxel, stabilize micro-tubules and have shown significant clinical activity, but factors ...
- Discontinued drugs, 2007: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs
[作者:Antoniu, SA,期刊:Expert opinion on investigational drugs, 页码:1651-1661 , 文章类型: Article,,卷期:2008年17-11]
This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 17 pulmonary-allergy, dermatological, gastrointes...
|